Clinical trials: psoriasis
DLQI, PHQ-9
To Evaluate the Mechanism of Jing Si Herbal Tea Liquid Packets and Traditional Western Medicine for Psoriasis
Psoriasis is a chronic cutaneous inflammatory disease due to immune dysregulation. It caused skin lesions with thickening plaques and heavy silver scales over the patient's body surface area, including nail deformity, often…
- Conditions
- DLQI, PHQ-9, PSAI, Serum Cytokine Survey
- Trial name
- NCT05436938
- Testing
- Jing Si herbal tea liquid packets use
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Psoriasis, Atopic Dermatitis
Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional Chinese Medicine
This study is a cross-sectional, observational investigation designed to develop and validate a noninvasive ocular imaging-based predictive model for major inflammatory skin diseases, including psoriasis, atopic dermatitis, and…
- Trial name
- NCT07434076
- Testing
- Questionnaire collection
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Plaque Psoriasis
Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index
Psoriasis (PsO) is a common chronic relapsing inflammatory disease, induced by a combination of genetic and environmental effects, which seriously affects the quality of life of patients.Psoriasis Area and Severity Index（PASI…
- Trial name
- NCT06579976
- Testing
- No intervention
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis
In this open-label, multi-center, observational, post-marketing surveillance study, patients with ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis received biosimilar etanercept 25 mg twice weekly or 50 mg…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- ASQA (NCT04582084)
- Testing
- Etanercept
- Where
- 10 sites in Iran
- Volunteers
- 583 people
- Sponsor
- AryoGen Pharmed Co.
Psoriatic Arthritis
A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
This study is designed to assess the efficacy of apremilast, either in monotherapy or with stable methotrexate, on imaging outcomes in adults with active psoriatic arthritis with less than 5 years of disease duration (since…
- Trial name
- MOSAIC (NCT03783026)
- Testing
- Apremilast
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 123 people
- Sponsor
- Amgen
Psoriasis
Alefacept Mechanism of Action in Psoriasis
To determine the mechanism of action of alefacept in patients with psoriasis.
- Trial name
- NCT00150982
- Testing
- Mechanism of action of alefacept
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Plaque Psoriasis
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01483924
- Testing
- Apo805K1
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Atopic Dermatitis, Psoriasis Vulgaris
Blue Light in the Treatment of Inflammatory Skin Diseases
The goal of this clinical trial is to assess the effectiveness of full-body blue light irradiations in the treatment of inflammatory skin diseases (atopic dermatitis, psoriasis, eczema) and chronic pruritus in adult and pediatric…
- Conditions
- Atopic Dermatitis, Psoriasis Vulgaris, Eczema, Pruritus
- Trial name
- NCT06516783
- Testing
- Full Body Blue GEN 1.0 device
- Where
- Poland
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Chronic Plaque Psoriasis
The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
The main purpose of this study is to assess the effect of smoking status on the success of Etanercept therapy in patients with moderate-to-severe psoriasis.
- Trial name
- NCT02570750
- Testing
- QUESTIONNAIRE ON SMOKING HABITS
- Where
- 30 sites in Romania
- Volunteers
- 183 people
- Sponsor
- Pfizer
Generalized Pustular Psoriasis
Biologic Therapy for Generalized Pustular Psoriasis
The investigators aim to compare the efficacy and safety of secukinumab and ustekinumab in patients with generalized pustular psoriasis (GPP), and to explore the impact of genetic mutation types on clinical efficacy.
- Trial name
- NCT06391996
- Testing
- After exclusion of relevant contraindications, participants received subcutaneous ustekinumab/secukinumab therapy.
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Chao Ji
Psoriasis
Pioglitazone in Psoriasis- A Clinical and Molecular Study.
The study will assess the effectiveness of Pioglitazone on cellular and clinical levels in terms of improvement of both skin and systemic manifestations of psoriasis.
- Trial name
- NCT01133561
- Testing
- actozone A, actozone B
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Cairo University
Plaque Psoriasis
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the potential to suppress the adrenal glands and…
- Trial name
- NCT03992261
- Testing
- Halobetasol Topical Foam
- Where
- 11 sites in United States, Georgia and 2 more
- Volunteers
- 24 people
- Sponsor
- Mayne Pharma International Pty Ltd
Psoriasis, Plaque Type Psoriasis
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
- Conditions
- Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
- Trial name
- AURIEL-PsO (NCT02660580)
- Testing
- MSB11022, Humira®
- Where
- 76 sites in United States, Bulgaria and 10 more
- Volunteers
- 443 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Psoriasis
Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Dendritic cells are a key component of the inflammatory response seen in psoriasis. Several current psoriasis therapies have been shown to reduce the number of dendritic cells in patients with psoriasis, leading researchers to…
- Trial name
- NCT01987609
- Testing
- Hylenex, Normal Saline
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Tissa Hata, MD
Rheumatoid Arthritis, Ankylosing Spondylitis
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Treatment with tumor necrosis factor (TNF) inhibitors, especially adalimumab, demonstrated an improvement in work productivity in participants with rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01282372
- Volunteers
- 500 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Pyoderma Gangrenosum, Hidradenitis Suppurativa
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
The investigators hypothese that Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway play a key role in pathophysiology of pyoderma gangrenosum (PG).
- Conditions
- Pyoderma Gangrenosum, Hidradenitis Suppurativa, Psoriasis
- Trial name
- NCT04792957
- Testing
- immunohistochemical methods
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Dokuz Eylul University
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Psoriasis, Atherosclerotic Cardiovascular Disease
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
Background: Psoriasis causes chronic inflammation in the body. Researchers want to see if a kind of vitamin B3 dietary supplement can help. This might lead to more treatment options.
- Conditions
- Psoriasis, Atherosclerotic Cardiovascular Disease, Obesity, Dyslipidemia
- Trial name
- NCT04271735
- Testing
- Niagen
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Psoriasis
Risankizumab Long-term Remission Study
Although the newly developed biologics (drugs derived from living cells cultured in a laboratory) are highly effective in controlling psoriasis, all the biologics should be continuously injected to suppress recurrence of the…
- Trial name
- NCT04630652
- Testing
- Risankizumab-Rzaa, Punch biopsies of the skin at baseline visit, Punch biopsies of the skin at week 28 visit
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jaehwan Kim
Psoriasis
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.
- Trial name
- PSORITUS (NCT02362789)
- Testing
- Secukinumab
- Where
- 19 sites in Germany
- Volunteers
- 132 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.